BTK and B-cell non-Hodgkin lymphoma: While emavusertib has shown efficacy when combined with ibrutinib and PI3K inhibitors even in patients with secondary resistance to these agents (68), there is rationale to combine emavusertib with next generation inhibitors of the BTK pathway such as non-covalent BTK inhibitors and BTK degraders given the impressive efficacy of these agents in several heavily pre-treated B-cell NHL patients that developed disease progression after prior treatment with a covalent BTK inhibitor and even prior PI3K inhibitors (85, 86).